Our Pricing

Understanding Wegovy Pricing in the UK: Transparent Costs and Discount Codes

Published on: June 03, 2026

Searching for clear wegovy pricing uk discount code information? At Cured Pharmacy, Wegovy starts from £79.00 with our exclusive discount code WEIGHTLOSSNEW, offering transparent upfront pricing before your free clinical consultation. Unlike many providers who hide costs until after assessment, we believe UK patients deserve clarity from the start.

How Wegovy Pricing Works at UK Pharmacies

Wegovy (semaglutide) is a prescription-only weight loss injection licensed by the MHRA for chronic weight management in adults with a BMI of 30 kg/m² or greater, or 27 kg/m² with weight-related comorbidities [1]. At Cured Pharmacy, transparent pricing starts from £79.00 per pen, with the final cost determined by your prescribed dose following clinical assessment by our UK-registered prescribers.

The medication works by mimicking GLP-1, a naturally occurring hormone that regulates appetite and food intake. In the landmark STEP 1 trial, participants achieved an average 14.9% body weight reduction over 68 weeks when combined with lifestyle interventions [2]. Your treatment journey typically begins with a 0.25mg weekly dose, gradually titrating up to the maintenance dose of 2.4mg as tolerated.

Our superintendent pharmacist Tarun Kumar (GPhC 2233073) ensures every prescription meets UK regulatory standards. The pricing structure reflects the actual dose prescribed—lower doses during the initial titration phase cost less than maintenance doses, allowing patients to budget accurately throughout their weight management programme.

Applying Your Wegovy Discount Code WEIGHTLOSSNEW

The discount code WEIGHTLOSSNEW provides £20 off first order using code WEIGHTLOSSNEW

To use your discount code, complete the free online consultation which takes under three minutes. Our UK-registered clinical team will assess your medical history, current medications, and weight management goals to determine if Wegovy is clinically appropriate. If approved, the discount applies immediately to your first prescription, with transparent pricing displayed before payment.

Eligibility Requirements for Wegovy Treatment

UK prescribers assess several clinical criteria before approving Wegovy. You must have a BMI of 30 kg/m² or above, or 27 kg/m² with at least one weight-related health condition such as type 2 diabetes, hypertension, or obstructive sleep apnoea [1]. The prescriber will also review contraindications including personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, or severe gastrointestinal disease.

Our clinical team evaluates your complete medical profile during the consultation. Previous weight loss attempts, current medications, and realistic treatment expectations all factor into the prescribing decision, ensuring Wegovy is both safe and appropriate for your individual circumstances.

Wegovy Dosing Schedule and Monthly Costs

Wegovy follows a structured dose escalation protocol designed to minimise gastrointestinal side effects while achieving optimal weight loss outcomes. The standard titration schedule begins at 0.25mg weekly for four weeks, increasing to 0.5mg, then 1mg, 1.7mg, and finally the maintenance dose of 2.4mg weekly [3]. Each pen contains four weekly doses at the prescribed strength.

Monthly costs vary depending on your current dose level. During the initial 0.25mg phase, costs are lower than the maintenance 2.4mg dose, though our transparent pricing structure ensures you know exactly what to expect at each stage. Most patients reach the maintenance dose within 16 to 20 weeks, subject to individual tolerance and clinical response.

If you experience persistent gastrointestinal side effects during dose escalation, your UK prescriber may recommend remaining at your current dose for an additional four weeks before increasing. This personalised approach prioritises tolerability while working towards the therapeutic dose demonstrated effective in clinical trials [2].

What Happens If You Miss a Dose

If you miss a Wegovy injection and the next scheduled dose is more than two days away, take the missed dose as soon as possible. If less than two days remain until your next dose, skip the missed dose and resume your regular schedule [3]. Never double up doses to compensate for a missed injection, as this increases the risk of gastrointestinal side effects including nausea, vomiting, and diarrhoea.

Comparing Wegovy Pricing Across UK Weight Loss Treatments

The UK weight loss treatment market includes several prescription options, each with distinct mechanisms, dosing schedules, and pricing structures. Wegovy represents the once-weekly semaglutide injection option, while alternatives include daily injections and dual-pathway medications. Understanding these differences helps patients make informed decisions aligned with their clinical needs and budget.

When evaluating treatment costs, consider the total monthly expense including all required doses. Weekly injections like Wegovy require four pens monthly at the maintenance dose, while daily injection options require significantly more frequent administration. Our transparent pricing model displays costs before consultation, eliminating surprise fees common at other providers.

Clinical efficacy also factors into value assessment. The STEP trials demonstrated semaglutide's robust weight loss outcomes, with participants losing significantly more weight compared to placebo groups across multiple studies [2]. Your UK prescriber will discuss which treatment offers the best balance of efficacy, tolerability, and cost for your individual circumstances.

How Semaglutide Compares to Other Weight Loss Medications

Semaglutide belongs to the GLP-1 receptor agonist class, which works by mimicking the action of glucagon-like peptide-1 to reduce appetite and increase feelings of fullness. This mechanism differs from older weight loss medications like orlistat, which blocks fat absorption in the digestive system, or combination therapies that affect multiple neurotransmitter pathways [4].

Head-to-head trials show varying efficacy profiles across different weight loss medications. The STEP 2 trial specifically compared semaglutide 2.4mg against semaglutide 1mg (the dose used for type 2 diabetes) and placebo in adults with overweight or obesity, demonstrating superior weight loss with the higher 2.4mg dose [5]. More recent dual GIP/GLP-1 receptor agonists have shown even greater weight reductions in clinical trials, though individual response varies.

Your choice of medication should consider factors beyond just weight loss percentages. Injection frequency, side effect profiles, contraindications, and long-term safety data all matter. Our UK clinical team discusses these nuances during your consultation, ensuring your prescribed treatment aligns with your medical history and lifestyle preferences.

Lifestyle Modifications Alongside Medication

MHRA-licensed weight loss medications work most effectively when combined with reduced-calorie diet and increased physical activity. Clinical trials demonstrating semaglutide's efficacy included lifestyle intervention programmes, meaning the published weight loss percentages reflect combined medication and behaviour change [2]. Patients using medication alone without dietary modifications typically experience less significant results.

Our clinical team provides guidance on sustainable lifestyle changes during your consultation. Realistic calorie reduction, regular physical activity appropriate to your fitness level, and behavioural strategies for managing emotional eating all contribute to successful long-term weight management. Medication serves as a tool to make these changes more achievable, not a replacement for them.

What to Expect During Your Wegovy Treatment Journey

Starting Wegovy involves a comprehensive clinical assessment by our UK-registered prescribers, who evaluate your medical history, current health status, and weight management goals. The free online consultation takes under three minutes to complete and covers essential safety questions about contraindications, concurrent medications, and previous weight loss attempts. If approved, your prescription is dispensed from our UK-registered pharmacy (GPhC 9012511) with discreet packaging and tracked delivery.

During the first month at the 0.25mg starter dose, many patients notice reduced appetite and earlier satiety during meals. Some experience mild gastrointestinal side effects including nausea or occasional loose stools, which typically diminish as your body adjusts to the medication [3]. Keeping well-hydrated, eating smaller portions, and avoiding high-fat meals can help minimise these effects during dose escalation.

Weight loss typically accelerates as you progress through higher doses, with most significant reductions occurring once you reach the 2.4mg maintenance dose. Clinical trials showed continued weight loss throughout the 68-week study period, with participants maintaining lower body weight at the trial's conclusion [2]. Regular follow-up with your prescriber ensures your treatment remains safe and effective, with dose adjustments made if needed based on your individual response and tolerability.

Long-term weight management requires ongoing commitment to both medication and lifestyle modifications. Our clinical team remains available for questions throughout your treatment journey, and repeat prescriptions can be ordered conveniently through our online platform once your initial prescription is established. Transparent pricing continues for all repeat orders, with the same discount code benefits applying to ongoing treatment.

Scientific References

1. Medicines and Healthcare products Regulatory Agency. (2023). Wegovy 0.25 mg solution for injection in pre-filled pen - Summary of Product Characteristics. GOV.UK. https://products.mhra.gov.uk/ [accessed 13 August 2026]
2. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
3. Novo Nordisk. (2023). Wegovy (semaglutide) injection: Prescribing Information. Novo Nordisk Inc. https://www.novonordisk.com/ [accessed 13 August 2026]
4. National Institute for Health and Care Excellence. (2023). Obesity: identification, assessment and management (CG189). NICE Guidelines. https://www.nice.org.uk/guidance/cg189 [accessed 13 August 2026]
5. Davies, M., Færch, L., Jeppesen, O. K., et al. (2021). Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet, 397(10278), 971–984. https://doi.org/10.1016/S0140-6736(21)00213-0 [accessed 13 August 2026]
6. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
7. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
8. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Weight loss results vary between individuals and depend on adherence to prescribed treatment and lifestyle modifications.